Indian Covid vaccines better than Pfizer, Moderna says Adar Poonawalla

Covid vaccines

Adar Poonawalla, chief executive officer, Serum Institute of India
Adar Poonawalla, chief executive officer (CEO) of Serum Institute of India (Photo: PTI image)
ANI General News
2 min read Last Updated : Apr 13 2022 | 3:03 PM IST

 

New Delhi [India], April 13 (ANI): Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday claimed that "Made in India" COVID-19 vaccines have provided more protection against the coronavirus infection than mRNA vaccines like Pfizer and Moderna.

Speaking to ANI, the SII CEO said, "The COVID-19 vaccines which have been made in India are providing more protection against the disease than mRNA vaccines like Pfizer and Moderna."

"It's good that vaccines like Pfizer and Moderna are not introduced in India, because in countries like US people have taken 2nd and 3rd booster dose and still many are getting infected with Corona but in India, our vaccines have given good protection," Poonawala stated.

On being asked about the export of the Covishield COVID-19 vaccine, the SII CEO informed that India has exported it to more than 80 countries so far.

"We have exported Covishield to more than 80 countries and 10 crore doses so far. Now, the demand for COVID vaccine has been reduced due to declining cases," he added.

He also added that "In some countries where mRNA vaccine was given, many people were hospitalised and cases were reported in those countries because they were not providing good protection against the viral infection.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccinePfizer

First Published: Apr 13 2022 | 3:03 PM IST

Next Story